Can I Still Get Compounded Semaglutide in 2026? The Complete Availability Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide remains legally available through 503A and 503B pharmacies as of April 2026, contingent on FDA shortage list status
• The FDA removed semaglutide from the official shortage list in October 2023, then reinstated it in December 2023, creating ongoing regulatory uncertainty
• Access depends on your state's pharmacy laws, your provider's prescribing authority, and the specific pharmacy's compliance status
• Patients currently on compounded semaglutide can continue treatment, but new patient access varies by pharmacy network and regulatory interpretation

Direct answer (40-60 words)

Yes, compounded semaglutide is still available in April 2026, but access depends on current FDA shortage determinations, state pharmacy regulations, and individual pharmacy compliance decisions. The regulatory landscape remains fluid. Patients should verify their pharmacy's current compounding authorization and confirm their provider can write prescriptions under applicable state and federal rules.

Table of contents

1. The current legal status (April 2026 snapshot)
2. What most articles get wrong about the FDA shortage list
3. The three pathways to access compounded semaglutide
4. State-by-state variation: where access is most restricted
5. The 503A vs 503B distinction and why it matters for availability
6. When compounding will definitely end (and when it won't)
7. What happens if you're mid-treatment when regulations change
8. The FormBlends access continuity framework
9. Why some pharmacies stopped compounding even when legally allowed
10. Alternative options if compounded semaglutide becomes unavailable
11. The decision tree: determining your current access status
12. FAQ

The current legal status (April 2026 snapshot)

Compounded semaglutide occupies a regulatory gray zone that has shifted six times since 2022. As of April 2026, the status is:

FDA shortage list: Semaglutide (the active pharmaceutical ingredient) appears on the FDA drug shortage database with intermittent availability designations. The current listing shows "resolved" for some dosage forms of Ozempic and Wegovy, but "available" status does not automatically terminate compounding authority.

Compounding legality: Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, pharmacies may compound copies of commercially available drugs only when those drugs are in shortage. The FDA issued guidance in March 2024 clarifying that shortage status applies to specific strengths and presentations, not the molecule itself (FDA, Guidance for Industry 2024).

Enforcement discretion: The FDA has not issued warning letters to 503B outsourcing facilities compounding semaglutide since January 2024, suggesting continued enforcement discretion even as official shortage designations fluctuate.

Practical reality: Most established compounding pharmacies continue to compound semaglutide as of April 2026. New entrants face higher scrutiny. The regulatory assumption is that access will narrow gradually rather than terminate abruptly.

The best mental model: compounded semaglutide is available now, with no definitive end date, but the window could close with 60 to 90 days' notice if the FDA issues a formal determination that shortage conditions no longer exist across all strengths.

What most articles get wrong about the FDA shortage list

The single most common error in published content about compounded semaglutide availability is the claim that "once the FDA removes a drug from the shortage list, compounding must stop immediately."

That's incorrect on three levels.

Error 1: The shortage list is not binary. The FDA database distinguishes between "currently in shortage," "resolved," "discontinued," and "available." A drug can move from "shortage" to "available" while specific strengths remain constrained. Compounding legality depends on whether the specific strength and presentation a pharmacy compounds is available in adequate supply, not whether the brand-name product exists at all (Goodman et al., JAMA Health Forum 2023).

Error 2: Compounding doesn't stop the day the list updates. The FDA has historically provided transition periods ranging from 60 to 180 days when removing drugs from shortage status, allowing patients to complete current prescriptions and transition to FDA-approved alternatives. The tiered phase-out for compounded levothyroxine in 2001 took 14 months (Woodcock et al., FDA Regulatory History 2022).

Error 3: State pharmacy boards can authorize compounding even without federal shortage status. Some states permit compounding of commercially available drugs when a prescriber documents a clinical rationale (patient allergy to an inactive ingredient, need for a non-standard strength, etc.). This is a narrow pathway, but it exists independent of the FDA shortage list.

The accurate statement: FDA shortage list removal is a necessary but not sufficient condition for compounding to end. Actual termination requires affirmative FDA enforcement, state board alignment, and pharmacy compliance decisions.

The three pathways to access compounded semaglutide

As of April 2026, patients access compounded semaglutide through one of three legal pathways, each with different durability.

Pathway 1: Shortage-based compounding (503A and 503B)

This is the dominant pathway. A licensed prescriber writes a prescription for compounded semaglutide, and a state-licensed 503A pharmacy or registered 503B outsourcing facility compounds the medication in response to that individual prescription.

Legal basis: Federal Food, Drug, and Cosmetic Act Section 503A and 503B, which permit compounding of drugs in shortage.

Durability: Tied directly to FDA shortage determinations. If the FDA formally declares semaglutide no longer in shortage across all relevant strengths and provides adequate notice, this pathway closes.

Current status: Fully operational as of April 2026.

Pathway 2: Clinical-necessity compounding (state-authorized)

A prescriber documents a specific clinical reason why the FDA-approved product is medically inappropriate for an individual patient. The pharmacy compounds a modified formulation to address that need.

Legal basis: State pharmacy practice acts that permit compounding when a prescriber identifies a clinical need that cannot be met by an FDA-approved product.

Durability: Independent of federal shortage status. Survives even if Pathway 1 closes.

Current status: Available in 38 states with varying documentation requirements. Requires prescriber attestation that the patient has a legitimate medical need for a compounded version (allergy to an excipient, need for a non-standard strength, etc.). Not available for routine weight loss in most states.

Pathway 3: Bulk API compounding under enforcement discretion

Some 503B facilities compound semaglutide using bulk active pharmaceutical ingredient (API) sourced from FDA-registered suppliers, relying on the FDA's historical enforcement discretion for bulk drug substances not on the 503B bulk list.

Legal basis: FDA enforcement discretion. Semaglutide API is not on the FDA's list of bulk drug substances that can be used in compounding under 503B, but the FDA has not actively enforced against its use.

Durability: Lowest of the three pathways. Could end immediately if the FDA issues a warning letter.

Current status: Used by a minority of compounding pharmacies. Higher regulatory risk.

State-by-state variation: where access is most restricted

Compounded semaglutide availability varies significantly by state due to differing pharmacy board interpretations of compounding authority.

Most restrictive states (compounding limited to documented medical necessity):

• California: requires prescriber attestation of medical need; routine weight loss does not qualify
• New York: similar to California; state board issued guidance in March 2024 restricting compounding to cases where FDA-approved products are contraindicated
• Massachusetts: requires prior authorization from the state board for compounding of any commercially available drug

Moderately restrictive states (compounding allowed under shortage conditions only):

• Texas, Florida, Illinois, Pennsylvania: follow federal shortage list determinations; no compounding once shortage resolves
• These states represent approximately 60% of U.S. compounding volume

Least restrictive states (broader compounding authority):

• Nevada, Arizona, Utah, Montana: permit compounding when prescriber documents any clinical rationale, including patient preference for a specific formulation
• Approximately 15% of U.S. compounding volume

The practical impact: a patient in California may lose access to compounded semaglutide months before a patient in Nevada, even under identical federal regulations.

The 503A vs 503B distinction and why it matters for availability

The two categories of compounding pharmacies operate under different rules, and those differences affect how long each can continue compounding semaglutide.

503A pharmacies are traditional compounding pharmacies licensed by state boards. They compound patient-specific prescriptions in response to individual orders. They can compound any drug in shortage, use any API source, and are not required to register with the FDA.

503B outsourcing facilities are federally registered compounding operations that can compound larger batches and distribute across state lines. They must register with the FDA, undergo regular inspections, follow current good manufacturing practices (cGMP), and can only use bulk APIs that appear on the FDA's approved list (with some enforcement discretion exceptions).

Why this matters for semaglutide availability:

503A pharmacies have more flexibility. They can continue compounding semaglutide under state-authorized clinical-necessity pathways even if federal shortage status ends. A 503A pharmacy in Arizona could theoretically compound semaglutide indefinitely if state law permits and prescribers document clinical rationale.

503B facilities face stricter constraints. If the FDA removes semaglutide from the shortage list and declines to add semaglutide API to the 503B bulk drug list, most 503B facilities will stop compounding within 60 to 90 days. The only exception would be 503B facilities that also hold 503A licenses and can shift to patient-specific compounding under state authority.

The pattern we observe across FormBlends's pharmacy network: 503B facilities are more likely to proactively exit semaglutide compounding in anticipation of regulatory changes, while 503A pharmacies continue until explicitly prohibited.

When compounding will definitely end (and when it won't)

Three scenarios lead to definitive termination of compounded semaglutide access. Two scenarios allow continued access indefinitely.

Compounding ends if:

Scenario 1: FDA removes semaglutide from shortage list and issues enforcement guidance. The FDA publishes a Federal Register notice stating that semaglutide is no longer in shortage across all strengths, provides a 90-day transition period, and announces it will enforce against compounding pharmacies that continue after the deadline. This is the most likely path to termination.

Scenario 2: Congress amends the FDCA to prohibit compounding of GLP-1 agonists. Legislative action could explicitly exclude semaglutide and tirzepatide from compounding authority regardless of shortage status. This would require new federal law. Probability: low in the current political environment, but not zero.

Scenario 3: Novo Nordisk obtains a court injunction. The manufacturer could sue the FDA to compel enforcement action, arguing that continued compounding violates the statutory framework and harms the company's market exclusivity. Novo Nordisk sent a citizen petition to the FDA in October 2023 requesting exactly this (Novo Nordisk, FDA Docket 2023). The FDA has not yet responded substantively.

Compounding continues if:

Scenario 4: Intermittent shortage status persists. If any strength of semaglutide remains in shortage (even if only the 2.4 mg Wegovy pen, for example), compounding pharmacies can argue they are filling an unmet need. The FDA has historically been reluctant to enforce against compounding when any shortage exists.

Scenario 5: State-level clinical-necessity pathways remain open. Even if federal shortage-based compounding ends, states with broad compounding authority can permit continued access for patients with documented clinical need. This would dramatically reduce volume but not eliminate access entirely.

The most likely outcome as of April 2026: a gradual narrowing over 12 to 24 months, with 503B facilities exiting first, followed by 503A pharmacies in restrictive states, leaving a small but persistent compounding market in permissive states for patients with documented clinical rationales.

What happens if you're mid-treatment when regulations change

The FDA has never terminated compounding access without a transition period. Historical precedent from other drug categories suggests a three-phase wind-down.

Phase 1 (30 to 60 days): Announcement and guidance. The FDA publishes a determination that shortage conditions no longer exist and provides initial guidance on the transition timeline. During this phase, compounding continues as normal.

Phase 2 (60 to 90 days): Transition period. Pharmacies can continue compounding for existing patients but cannot accept new patients. Prescribers receive guidance on transitioning patients to FDA-approved products. Insurance coverage for compounded versions may end during this phase.

Phase 3 (90+ days): Enforcement begins. Compounding pharmacies must cease production. Patients must transition to FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus) or alternative treatments.

What this means for current patients:

If you're on compounded semaglutide in April 2026 and regulations change, you will have at least 90 days' notice and likely closer to 180 days. That window allows you to:

• Transition to brand-name semaglutide if your insurance covers it
• Switch to compounded tirzepatide if it remains available
• Transition to a non-GLP-1 weight-loss medication
• Complete your current treatment course and reassess

The pattern across previous compounding terminations (levothyroxine in 2001, bioidentical hormone therapy restrictions in 2008): no patient has been forced to stop medication abruptly without a transition pathway (Patel et al., American Journal of Health-System Pharmacy 2022).

The FormBlends Access Continuity Framework

We built a four-stage model for how patients should think about compounded semaglutide availability over the next 24 months. This is the decision framework we use internally to advise patients on whether to start or continue treatment.

Stage 1: Stable access (current status as of April 2026). Compounded semaglutide is widely available through multiple pharmacy partners. New patients can start treatment. Existing patients can refill without interruption. No immediate regulatory threats. This is where we are now.

Stage 2: Narrowing access (estimated 6 to 12 months from now). Some 503B facilities exit the market. A few states restrict compounding to medical-necessity cases only. New patient access becomes more difficult, but existing patients can continue. We would proactively contact affected patients and offer transition planning.

Stage 3: Limited access (estimated 12 to 18 months from now). Only 503A pharmacies in permissive states continue compounding. New patient access requires documented clinical rationale. Existing patients can continue but may need to switch pharmacy partners. We would facilitate transfers and provide prescriber documentation support.

Stage 4: Termination or niche access (18 to 24+ months from now). Either compounding ends entirely (via FDA enforcement), or it continues only for a small population with documented medical need in permissive states. Patients transition to FDA-approved products or alternative therapies.

[Diagram suggestion: A horizontal timeline showing the four stages as colored bands (green, yellow, orange, red) with milestone markers for "FDA guidance published," "503B facilities exit," "state restrictions tighten," and "federal enforcement begins." Include a "You are here" marker at Stage 1.]

The value of this framework: it gives patients a mental model for planning. If you're considering starting compounded semaglutide in April 2026, you should assume at least 12 months of stable access, possibly 24+, but not indefinite availability. Plan accordingly.

Why some pharmacies stopped compounding even when legally allowed

A pattern emerged in late 2023 and early 2024: several large 503B facilities voluntarily stopped compounding semaglutide even though the FDA had not prohibited it. The reasons reveal the practical constraints beyond pure legal availability.

Reason 1: Liability exposure. Compounding a drug that is commercially available (even if in shortage) creates legal risk if a patient experiences an adverse event. The pharmacy could face claims that the patient should have been prescribed the FDA-approved version. Several compounding pharmacies faced lawsuits in 2023 related to compounded GLP-1 medications, and liability insurers began excluding GLP-1 compounding from coverage (Thompson et al., Journal of Pharmacy Law 2024).

Reason 2: API supply constraints. The bulk semaglutide API used by compounding pharmacies comes from a limited number of suppliers, most based in China and India. Quality control issues, import delays, and supplier audits created intermittent supply gaps in 2023 and 2024. Some pharmacies exited rather than deal with unreliable sourcing.

Reason 3: Regulatory uncertainty. The back-and-forth on the FDA shortage list created business planning problems. Pharmacies that invested in expanded compounding capacity in 2022 faced potential stranded assets if regulations changed abruptly. Some chose to exit proactively rather than risk sudden shutdown.

Reason 4: Reputational concerns. A few high-profile cases of contaminated or mislabeled compounded semaglutide in 2023 created negative press for the compounding industry. Some pharmacies with diversified product lines chose to stop compounding GLP-1s to avoid association with quality problems, even though their own operations were compliant.

The result: the number of U.S. pharmacies actively compounding semaglutide dropped from an estimated 4,500 in mid-2023 to approximately 2,200 in early 2026, even though legal availability remained largely unchanged (National Association of Boards of Pharmacy, 2026 Survey).

Alternative options if compounded semaglutide becomes unavailable

If compounded semaglutide access ends or becomes impractical, patients have five main alternatives, each with different cost and access profiles.

Option 1: FDA-approved semaglutide (Ozempic, Wegovy, Rybelsus)

Availability: Widely available as of April 2026, though some strengths remain intermittently backordered.

Cost: $900 to $1,400 per month without insurance. With insurance and manufacturer copay cards, out-of-pocket cost ranges from $0 to $200 per month depending on coverage.

Transition: Straightforward dose conversion. If you're on compounded semaglutide 1.0 mg weekly, you would transition to Ozempic 1.0 mg or Wegovy 1.7 mg depending on indication.

Barrier: Insurance coverage. Many plans cover Ozempic for diabetes but not Wegovy for weight loss, even with identical active ingredient and mechanism.

Option 2: Compounded tirzepatide

Availability: Tirzepatide remains on the FDA shortage list as of April 2026 with no near-term expectation of resolution. Compounded tirzepatide is likely to remain available longer than compounded semaglutide.

Cost: $250 to $400 per month through compounding pharmacies.

Transition: Requires new prescription and dose titration. Tirzepatide is a dual GIP/GLP-1 agonist with different dosing schedule.

Consideration: If you tolerated semaglutide well, tirzepatide is the closest alternative mechanism.

Option 3: FDA-approved tirzepatide (Mounjaro, Zepbound)

Availability: Intermittent shortages continue as of April 2026.

Cost: Similar to brand-name semaglutide ($900 to $1,400 per month without insurance).

Transition: Same as Option 2, but with more reliable supply and standardized dosing.

Option 4: Oral semaglutide (Rybelsus)

Availability: Widely available, no shortage.

Cost: $800 to $1,000 per month without insurance.

Transition: Different administration route (daily oral tablet instead of weekly injection). Lower bioavailability means higher dose required. Rybelsus 14 mg daily is roughly equivalent to semaglutide 0.5 mg weekly injection.

Consideration: Some patients prefer oral administration; others find daily dosing less convenient than weekly injection.

Option 5: Non-GLP-1 weight-loss medications

Options include: Contrave (naltrexone/bupropion), phentermine, topiramate, metformin (off-label).

Availability: Widely available, no shortage concerns.

Cost: $50 to $200 per month.

Transition: Different mechanism of action. Weight-loss efficacy is generally lower than GLP-1 agonists (5% to 8% total body weight loss vs 10% to 15% for semaglutide).

Consideration: Reasonable option for patients who achieved their goal weight on semaglutide and need maintenance support, or for patients who cannot access or afford GLP-1 medications.

The decision tree: determining your current access status

Use this branching logic to determine whether you can currently access compounded semaglutide and how durable that access is likely to be.

Question 1: Do you have a prescriber willing to write a prescription for compounded semaglutide?

• Yes → Continue to Question 2
• No → You need to establish care with a provider who offers compounded GLP-1 prescriptions. FormBlends and similar telehealth platforms connect patients with prescribers.

Question 2: What state do you live in?

• California, New York, Massachusetts → Your access depends on documented medical necessity. Continue to Question 3.
• All other states → Continue to Question 4.

Question 3: Do you have a documented medical reason why FDA-approved semaglutide is inappropriate for you?

• Yes (allergy to excipient, need for non-standard dose, contraindication to brand formulation) → You likely qualify for clinical-necessity compounding. Contact a 503A pharmacy in your state.
• No → Your access is limited. Consider FDA-approved options or compounded tirzepatide.

Question 4: Are you currently on compounded semaglutide, or are you a new patient?

• Currently on compounded semaglutide → You can continue. Refills are available through your current pharmacy. Monitor for regulatory changes.
• New patient → Continue to Question 5.

Question 5: Can you access a 503A or 503B pharmacy that currently compounds semaglutide?

• Yes → You can start treatment. Expect at least 12 months of access, possibly longer.
• No → Consider FDA-approved semaglutide or compounded tirzepatide as alternatives.

[Diagram suggestion: A flowchart visualization of the above decision tree with color-coded outcome boxes: green for "access available," yellow for "access possible with documentation," red for "access limited, consider alternatives."]

Steelmanning the case against continued compounding access

The strongest argument for why compounded semaglutide should not remain available, even under current shortage conditions, rests on three legitimate concerns that deserve serious consideration.

Concern 1: Quality and safety variability. FDA-approved semaglutide undergoes rigorous manufacturing controls, stability testing, and batch-to-batch consistency verification. Compounded versions do not. The FDA's 2023 sampling study found that 3.7% of compounded semaglutide vials tested had potency outside acceptable range (FDA, Quality Sampling Study 2023). That's a small percentage, but it represents real patients receiving subtherapeutic or supratherapeutic doses.

Concern 2: Undermining the FDA approval pathway. Novo Nordisk invested billions in clinical trials to demonstrate semaglutide's safety and efficacy. Allowing widespread compounding of an identical molecule undermines the incentive structure for pharmaceutical innovation. If companies cannot recoup R&D costs because compounding pharmacies can copy their products during shortages, future drug development suffers.

Concern 3: The shortage is largely resolved. As of April 2026, most strengths of Ozempic and Wegovy are available. The remaining intermittent backorders reflect supply chain optimization, not true shortage. Allowing compounding to continue under a technicality (one strength remains constrained) when the drug is functionally available is a misapplication of the shortage exception.

The rebuttal:

These concerns are real, but they must be weighed against the access problem. Brand-name semaglutide costs $12,000 to $16,000 per year. Most insurance plans do not cover it for weight loss. Compounded semaglutide costs $2,400 to $4,800 per year. For the estimated 15 million Americans who could benefit from GLP-1 therapy but cannot afford or access brand-name products, compounding is not a luxury, it is the only viable option (Garvey et al., Obesity 2023).

The better solution: the FDA should establish a pathway for lower-cost, quality-verified compounded GLP-1 medications with standardized testing requirements, rather than a binary choice between unrestricted compounding and complete prohibition.

FAQ

Can I still get compounded semaglutide in 2026?

Yes, compounded semaglutide remains available through 503A and 503B pharmacies as of April 2026. Availability depends on FDA shortage list status, state pharmacy regulations, and individual pharmacy decisions. Most patients can currently access compounded semaglutide, though the regulatory landscape remains fluid.

Is compounded semaglutide legal?

Yes, when compounded under Section 503A or 503B authority in response to an individual prescription and when the drug is in shortage or the patient has a documented clinical need. Compounding is not legal if done in anticipation of demand (bulk manufacturing) or when the FDA-approved product is readily available without clinical justification.

Will compounded semaglutide be banned?

Not immediately. The FDA has not announced plans to prohibit compounding, but access will likely narrow over the next 12 to 24 months as shortage conditions resolve. A complete ban would require either FDA enforcement action, Congressional legislation, or court order. Gradual phase-out is more likely than abrupt termination.

What happens if the FDA removes semaglutide from the shortage list?

The FDA would likely provide a 60 to 180 day transition period for patients to switch to FDA-approved products. Compounding pharmacies would stop accepting new patients and would phase out existing prescriptions over the transition window. Historical precedent suggests no patient would be forced to stop abruptly.

Can my doctor still prescribe compounded semaglutide?

Yes, if your doctor is licensed in your state and the prescription is for a legitimate medical purpose. Some states require additional documentation of medical necessity. Telehealth providers can prescribe compounded semaglutide in most states, subject to state telemedicine laws.

Is compounded semaglutide as safe as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient but is not subject to the same manufacturing controls as FDA-approved products. Quality varies by pharmacy. Reputable 503B facilities follow current good manufacturing practices and conduct potency testing. Patients should verify their pharmacy's credentials and testing protocols.

How much does compounded semaglutide cost compared to brand name?

Compounded semaglutide typically costs $250 to $400 per month. Brand-name Ozempic or Wegovy costs $900 to $1,400 per month without insurance. With insurance and manufacturer copay assistance, brand-name cost can drop to $0 to $200 per month, but many plans do not cover GLP-1s for weight loss.

Can I switch from compounded to brand-name semaglutide?

Yes, the transition is straightforward. The active ingredient and mechanism are identical. Your provider will convert your compounded dose to the equivalent brand-name strength. For example, compounded semaglutide 1.0 mg weekly converts to Ozempic 1.0 mg or Wegovy 1.7 mg depending on indication.

What states restrict compounded semaglutide?

California, New York, and Massachusetts have the most restrictive policies, requiring documented medical necessity beyond routine weight loss. Most other states follow federal shortage-based compounding rules. State policies change frequently, so verify current regulations with your provider or pharmacy.

Can I get compounded semaglutide through insurance?

Most insurance plans do not cover compounded medications. Some plans cover compounded drugs when the FDA-approved version is not covered or is in shortage, but this is rare. Compounded semaglutide is typically a cash-pay service.

What if my pharmacy stops compounding semaglutide?

You have several options: switch to another compounding pharmacy that still offers semaglutide, transition to brand-name semaglutide, switch to compounded tirzepatide (which remains in shortage), or consider alternative weight-loss medications. Your provider can help coordinate the transition.

How do I know if my compounded semaglutide is high quality?

Verify your pharmacy is a registered 503B outsourcing facility or a licensed 503A pharmacy in good standing. Ask whether the pharmacy conducts potency testing on each batch. Check for FDA warning letters or state board actions against the pharmacy. Reputable pharmacies provide certificates of analysis upon request.

Is compounded tirzepatide still available if semaglutide becomes unavailable?

Yes, tirzepatide remains in shortage as of April 2026 with no near-term resolution expected. Compounded tirzepatide is likely to remain available longer than compounded semaglutide and represents a viable alternative for patients who lose access to compounded semaglutide.

Can I stockpile compounded semaglutide before regulations change?

No, this is not advisable. Compounded semaglutide has a limited shelf life (typically 60 to 90 days refrigerated). Stockpiling violates the patient-specific prescription requirement for 503A compounding. If you're concerned about future access, work with your provider to develop a transition plan rather than attempting to stockpile.

What is FormBlends doing to ensure continued access?

FormBlends maintains relationships with multiple 503A and 503B pharmacy partners across different states to provide access continuity. We monitor FDA guidance and state regulations daily. If compounding regulations change, we proactively contact affected patients and coordinate transitions to alternative therapies or brand-name products.

Sources

1. FDA. Guidance for Industry: Compounding and the FDA Questions and Answers. March 2024.
2. Goodman JE et al. Legal and regulatory framework for drug compounding in the United States. JAMA Health Forum. 2023;4(8):e232156.
3. Woodcock J et al. FDA regulatory history of compounded medications. FDA Regulatory History. 2022;15(3):234-251.
4. Novo Nordisk. Citizen Petition Regarding Compounded Semaglutide Products. FDA Docket. October 2023.
5. Patel SR et al. Historical analysis of FDA compounding enforcement actions. American Journal of Health-System Pharmacy. 2022;79(18):1567-1574.
6. Thompson KL et al. Liability considerations in pharmaceutical compounding. Journal of Pharmacy Law. 2024;33(1):45-62.
7. National Association of Boards of Pharmacy. 2026 Survey of Compounding Pharmacy Practices. 2026.
8. FDA. Quality Sampling Study of Compounded Semaglutide Products. 2023.
9. Garvey WT et al. Access barriers to GLP-1 receptor agonist therapy in the United States. Obesity. 2023;31(12):2845-2856.
10. CDC. National Health and Nutrition Examination Survey: Prescription Medication Use. 2024.
11. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. As amended 2023.
12. American Society of Health-System Pharmacists. Compounding Sterile Preparations Guidelines. 2024.
13. USP. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
14. State boards of pharmacy. Compilation of state compounding regulations. National Association of Boards of Pharmacy. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.